The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Sotorasib vs adagrasib in the 2L+ setting: Outcomes in a large, multi-institutional, real-world database of KRAS-G12C mutated mNSCLC.
 
Adam Barsouk
No Relationships to Disclose
 
Maxim Yaskolko
No Relationships to Disclose
 
Jonathan Sussman
No Relationships to Disclose
 
Lova Sun
Consulting or Advisory Role - AstraZeneca; Bayer; Genmab/Seagen; GlaxoSmithKline; Guardant Health; Merus; Pfizer
Research Funding - Abbvie (Inst); Blueprint Medicines (Inst); Erasca, Inc (Inst); Frontier Medicines (Inst); Immunocore (Inst); IO Biotech (Inst); Merus (Inst); ORIC Pharmaceuticals (Inst); Seagen (Inst); Tempus (Inst)
 
Roger Cohen
Consulting or Advisory Role - Actuate Therapeutics; Genmab
Research Funding - Chugai Pharma (Inst); Janux Therapeutics (Inst); Prelude Therapeutics (Inst); Sensei Biotherapeutics (Inst)
 
Charu Aggarwal
Consulting or Advisory Role - Abbvie; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Novocure; Pfizer
Speakers' Bureau - AstraZeneca (I)
Research Funding - AstraZeneca/MedImmune (Inst); Candel Therapeutics (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Genmab; Loxo@Lilly (Inst); Merck Sharp & Dohme (Inst)
 
Corey Langer
Honoraria - AstraZeneca; Boehringer Ingelheim; Genentech/Roche; Lilly/ImClone; Merck; Pfizer; Takeda Science Foundation
Consulting or Advisory Role - Abbott Biotherapeutics; ARIAD; AstraZeneca; Bayer/Onyx; Bristol-Myers Squibb; Cancer Support Community; Celgene; Clarient; Clovis Oncology; Genentech/Roche; Gilead Sciences; Lilly/ImClone; Merck; Novocure; Pfizer; Regeneron; Takeda
Research Funding - Advantagene (Inst); Amgen; Ariad (Inst); AstraZeneca; Celgene (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Incyte; Inovio Pharmaceuticals (Inst); Johnson & Johnson/Janssen; Lilly; Merck (Inst); Novocure (Inst); Stem CentRx (Inst); Trizell (Inst)
Other Relationship - Amgen; Lilly; OncoCyte; Peregrine Pharmaceuticals; Summit Therapeutics; Synta; Veteran’s Health Administration Radiation Oncology Quality Surveillance Program Services
 
Melina Marmarelis
Stock and Other Ownership Interests - Johnson & Johnson; Merck
Honoraria - Janssen Oncology; Takeda
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Daiichi Sankyo/Astra Zeneca; Janssen Oncology; NEUVOGEN
Research Funding - AstraZeneca (Inst); Genentech (Inst); Ikena Oncology (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Regeneron